Nephrology and Hypertension

  • Research Faculty

  • Show All

    Division Head

    A photo of Prasad Devarajan.

    Prasad Devarajan, MD Director, Division of Nephrology and Hypertension

    researches acute kidney injury mechanisms, biomarkers and novel therapies. He also studies focal segmental glomerulosclerosis pathogenesis and biomarkers; and lupus nephritis molecular pathways and biomarkers. For each condition, his team employs an integrated approach of genomic and proteomic discovery in animal and human models, followed by translation, and validation in the human disease states.
    Visit the Devarajan Lab.

    513-636-4531
    prasad.devarajan@cchmc.org

    Prasad Devarajan, MD

    Director, Division of Nephrology and Hypertension

    Medical Director, Stone Center

    Director, Nephrology and Hypertension Clinical Laboratory

    Louise M. Williams Endowed Chair

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-4531

    Fax: 513-636-7407

    Email: prasad.devarajan@cchmc.org

    Show All

    Specialties

    Clinical specialties: Acute kidney injury, nephrotic syndrome, kidney stones

    Visit the Devarajan Lab.

    Education and Training

    Premedical Studies: Bombay University, India, 1979. 

    MD: Bombay University, India, 1985.

    Publications

    View PubMed Publications

    Faculty

    A photo of Michael Bennett.

    Michael R. Bennett, PhD Director, Biomarker Laboratory

    research interests include developing early diagnostic markers for pediatric diseases, such as acute kidney injury, nephrotic syndrome and lupus nephritis. Dr. Bennett is also interested in unraveling the etiology of focal segmental glomerulosclerosis by studying both the underlying genetic and proteomic patterns associated with the disease. 

    513-636-8349
    michael.bennett@cchmc.org

    Michael R. Bennett, PhD

    Director, Biomarker Laboratory

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-8349

    Email: michael.bennett@cchmc.org

    Show All

    Specialties

    Diagnostic markers for pediatric diseases; acute kidney injury; nephrotic syndrome, lupus nephritis; focal segmental glomerulosclerosis; mechanisms of neurologic disease

    Education and Training

    Research Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    PhD: University of Cincinnati College of Medicine, Cincinnati, OH, 2004.

    BA: Thomas More College, Crestview Hills, KY, 1997.

    Publications

    View PubMed Publications
    A photo of Bradley P. Dixon.

    Bradley P. Dixon, MD Pediatric Nephrologist

    focuses on the recognition and repair of DNA damage within the urinary microenvironment, specifically as it relates to the increased risk of malignancy in the augmented bladder. Dr. Dixon also has clinical and translational research interests in complement-mediated diseases such as atypical hemolytic uremic syndrome, as well as cystic kidney diseases such as tuberous sclerosis and polycystic kidney disease.
    Visit the Dixon Lab.

    513-636-4531
    bradley.dixon@cchmc.org

    Bradley P. Dixon, MD

    Pediatric Nephrologist

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4531

    Fax: 513-636-7407

    Email: bradley.dixon@cchmc.org

    Show All

    Specialties

    DNA damage response; DNA repair; hyperosmolal microenvironments; atypical hemolytic uremic syndrome; thrombotic microangiopathies; complement-mediated renal diseases.

    Visit the Dixon Lab.

    Biography

    Bradley Dixon, MD, joined the faculty in the Division of Nephrology and Hypertension at Cincinnati Children's in 2006. He has received support for his research from a William Cooper Procter Pediatric Research Award in 2006, a Child Health Research Career Development Award (K12) in 2009, and is currently funded by a K08 through the National Institute of Diabetes, Digestive and Kidney Diseases. Dr. Dixon’s research interests focus on the effects of hyperosmolal microenvironments such as the renal medulla and urinary bladder upon vital cellular processes such as the DNA damage response pathway and activation of cell cycle checkpoints and apoptosis. This research focus attempts to understand the susceptibility of the gastrointestinal tissues used in bladder reconstructions to carcinogenesis.

    In addition to his basic science research interests, Dr. Dixon has a clinical research interest in thrombotic microangiopathies such as atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), and is an investigator in a number of clinical trials and registries for these diseases. Dr. Dixon is also involved in clinical research studying cystic kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD).

    Education and Training

    BA: College of Wooster, Wooster, OH, 1995.

    MD: University of Tennessee, Memphis, 1999.

    Residency: Cincinnati Children's Hospital Medical Center, 1999-2002.

    Chief Residency: Cincinnati Childrens Hospital, 2002-2003.

    Fellowship: Cincinnati Childrens Hospital, 2003-2006.

    Publications

    View PubMed Publications

    Grants

    DNA Damage and Response in the Bladder Microenvironment. Principal Investigator. National Institutes of Health. Jul 2011 - Apr 2015. #K08 DK081737.
    A photo of Elif Erkan.

    Elif Erkan, MD, MS Pediatric Nephrologist

    is a physician scientist whose research interests are proteinuria induced injury in the kidney and the mechanism of albumin endocytosis in the proximal tubule epithelial cells. Her laboratory studies the protein-protein interactions between endocytic receptors/adapters and protein kinases that are involved in cell signaling events.

    513-636-4531
    elif.erkan@cchmc.org

    Elif Erkan, MD, MS

    Pediatric Nephrologist

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-4531

    Email: elif.erkan@cchmc.org

    Show All

    Specialties

    Clinical

    Proteinuria; nephrotic syndrome.

    Research

    Proteinuria induced tubular injury; tubular apoptosis; albumin endocytosis.

    Biography

    Dr. Elif Erkan received the prestigious SPR Fellow's Basic Research Award upon completion of her pediatric nephrology fellowship. She pursued a career as a physician scientist and continued to investigate the mechanism of proteinuria induced injury in proximal tubule cells following her fellowship. Her laboratory demonstrated an important link between endocytic adapter protein disabled-2 (Dab2) that binds to the cytoplasmic tail of albumin receptor megalin and protein kinase B (Akt). She received a NIH career development-KO8 award to support her studies elucidating the link between albumin endocytosis and cell signaling events.

    Education and Training

    MD: Ankara University School of Medicine, Ankara, Turkey, 1990.

    Residency: Pediatrics, Marmara University Hospital, Istanbul, Turkey, 1992-1997.

    Residency: Pediatrics, Montefiore Medical Center, Albert Einstein School of Medicine, Bronx, NY, 2000-2002.

    Fellowship: Pediatric Nephrology, Montefiore Medical Center, Albert Einstein School of Medicine, Bronx, NY, 1997-2000.

    MS: Clinical Research Methods Montefiore Medical Center, Albert Einstein School of Medicine, Bronx, NY, 1998-2001.

    Publications

    View PubMed Publications
    A photo of Jens W. Goebel.

    Jens W. Goebel, MD Clinical Director, Nephrology and Hypertension

    is involved in multi-center projects investigating non-invasive predictors of kidney transplant outcome and the influence of immunosuppressive regimens on transplantation tolerance. He is also conducting collaborative studies of the pharmacokinetics, genetics and dynamics of drugs used for anti-rejection prophylaxis, and participating in efforts to better understand our patients’ adherence to their immunosuppressive regimen.

    513-636-4531
    jens.goebel@cchmc.org

    Jens W. Goebel, MD

    Clinical Director, Nephrology and Hypertension

    Medical Director, Kidney Transplantation

    Clinical Director, Kidney Transplantation

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-4531

    Fax: 513-636-7407

    Email: jens.goebel@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Organ transplantation in children

    Research Interests

    Transplant-relevant immunology 

    Biography

    Dr. Goebel was recruited by Cincinnati Children's Hospital Medical Center in 2002 from the University of Kentucky to enhance the institution's kidney transplant program. His efforts along these lines focus both on further improving the clinical care of pediatric kidney transplant recipients and their families, as well as advancing basic and translational investigations into immunological aspects especially relevant to the field of transplantation.

    Education and Training

    MD: University of Heidelberg (Germany), 1991.

    Residency and Chief Residency: Department of Pediatrics, University of South Alabama, Mobile, AL, 1991 to 1995.

    Fellowship: Section of Pediatric Nephrology, Tulane University Medical Center, New Orleans, LA, 1995 to 1998.

    Certifications: General Pediatrics, 1994, 2002; Pediatric Nephrology, 1999.

    Publications

    View PubMed Publications

    Grants

    Center-PI / Co-Investigator / Collaborator:

    NIH UO1 grant: Noninvasive Monitoring to Predict Outcome in de novo Kidney Transplant Recipients (CTOT-01, Protocol Chair: P. Heeger, MD, City), commenced in late 2005 and ongoing

    NIH UO1 grant: Health and Literacy in Child and Adult Assessment: Expanded Testing of the Pediatric PROMIS (Patient Reported Outcomes Measurement Information System) Tool (Sponsor: D. DeWalt, MD, MPH, ), ongoing

    NIH UO1 grant: Chronic Kidney Disease in Children (CKID, PI: B. Warady, MD, Children’s Mercy Hospital, Kansas City, MO), ongoing

    NIH RO1 grant: Calcineurin Inhibitor Minimization And Foxp3+ Tregs Post-Transplant (PIs: Wayne Hancock, MD, Children’s , and John Bucuvalas, MD, Cincinnati Children’s Hospital), ongoing

    Midwest Pediatric Nephrology Consortium: Assessing and Implementing Transition to Adult Care in Children with CKD (PI: M. Ferris, MD, MPH, PhD, ), ongoing

    Amgen Pharmaceuticals: Pediatric Anemia Correction Study (Protocol 20050256), ongoing

    Roche Pharmaceuticals: Development of Population Pharmacokinetic models of Mycophenolic Acid for use in Bayesian Dose Individualization in Pediatric Kidney Transplant Patients (PI: A. Vinks, Cincinnati Children’s Hospital), ongoing

    Cincinnati Children’s Hospital Medical Center Outcomes Research Award: Validation of a Real-Time Adherence Assessment System (PI: A. Pai, PhD, Cincinnati Children’s Hospital), ongoing

    Cincinnati Children’s Hospital Medical Center Translational Research Initiative grant: Pharmacogenetics of Mycophenolic Acid in Kidney Transplant Patients (PI: A. Vinks, Cincinnati Children’s Hospital), ongoing

    Cincinnati Children’s Hospital Medical Center Translational Research Initiative grant: Biomarkers for Patient-tailored Therapies in Pediatric Lupus Nephritis using Mycophenolic Acid (PI: H. Brunner, Cincinnati Children’s Hospital), ongoing

    Cincinnati Children’s Hospital Medical Center Translational Research Initiative grant: Pharmacogenetics of IMPDH in Kidney Transplant Patients (PI: A. Vinks, Cincinnati Children’s Hospital), ongoing

    A photo of Stuart L. Goldstein.

    Stuart L. Goldstein, MD Director, Center for Acute Care Nephrology

    focuses on all aspects of acute kidney injury (AKI) spanning from translational work in AKI biomarker validation to long-term AKI epidemiology and outcomes. He is specifically interested in improving outcomes in the critically ill child with or at risk for AKI.

    513-803-3295
    stuart.goldstein@cchmc.org

    Stuart L. Goldstein, MD

    Director, Center for Acute Care Nephrology

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-803-3295

    Fax: 513-636-6407

    Email: stuart.goldstein@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Acute kidney injury; continuous renal replacement therapy; end-stage renal disease; health-related quality of life

    Research Interests

    Acute kidney injury epidemiology and biomarkers; health-related quality of life in ESRD; cardiovascular complications and inflammation in ESRD

    Biography

    Stuart L. Goldstein, MD has been an active investigator in the field of pediatric acute kidney injury (AKI) since 2000.  Dr.  Goldstein’s main research foci include: AKI epidemiology and outcomes, acute renal replacement therapy provision and investigation of novel urinary AKI biomarkers in the pediatric population.  Dr. Goldstein has established a strong record of interdisciplinary and inter-institutional collaboration with cardiologists, intensivists and emergency center physicians, which is evidenced by his establishment and directing of the Prospective Pediatric Continuous Renal Replacement Therapy Registry from 2001 to 2012, and the Prospective Pediatric AKI Research Group (ppAKI-RG) in 2012. The ppAKI-RG is comprised of 39 centers from around the world with the goal of improving outcomes for the child with or at-risk for, AKI. 

    Dr. Goldstein has led initial efforts to develop a standardized definition for pediatric AKI, assess novel AKI biomarkers in heterogeneous populations, and conceiving and validating stratification tools to identify patients at risk for AKI.  Building up these findings, Dr. Goldstein embarked on establishing the ppAKI-RG consortium to focus on multi-centered research studies that are dedicated to understanding and treating AKI in pediatric patients.  Currently, the ppAKI-RG has initiated three major, and unprecedented, national and international studies (AWARE, NINJA and DIRECT) to reduce AKI and improve patient outcomes.  Dr. Goldstein is also a recognized educator; he has developed the only pediatric specific Acute Care Nephrology sub-specialty fellowship with graduates who are now leaders in the field of pediatric AKI.

    Education and Training

    MD: Columbia College of Physicians and Surgeons, New York, NY, 1990.

    Residency: Baylor College of Medicine, Houston, TX.

    Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA.

    Publications

    View PubMed Publications

    Grants

    PlasmaLyte Gastroenteritis Study. Principal Investigator. Baxter Healthcare. Nov 2010 - Oct 2011.

    Inflammation, malnutrition and cardiac calcification in pediatric ESRD patients receiving dialysis- a comparison of hemodialysis vs. peritoneal dialysis. Principal Investigator. Baxter Healthcare. Dec 2010 - Dec 2011.

    Optimize Fluid Dosing in Critically Ill Children with Acute Kidney Injury. Principal Investigator. Casey Lee Ball Foundation. Jan 2011 – Dec 2011.

    Use of NGAL to Optimize Fluid Dosing, CRRT Initiation and Discontinuation in Critically Ill Children with Acute Kidney Injury. Principal Investigator. Casey Lee Ball Foundation. Feb 2011 - Jan 2012.

    Evaluation of cystatin C and Urine Proteins as Early Biomarkers of AKI in Children Treated with Nephrotoxic Medication. Principal Investigator. The Research Institute of McGill University Health Centre. Jun 2011 – Jun 2012.

    Center for Acute Care Nephrology Fellowship. Fellowship Director. Funded by Gambra Renal Products.  Jan 2011 - Jan 2013.

    Inflammation, malnutrition and cardiac calcification in pediatric ESRD patients receiving dialysis. Principal Investigator.  Casey Lee Ball Foundation. Jan 2010 - Dec 2020.

    A photo of Dr. David Hooper.

    David K. Hooper, MD, MS Pediatric Nephrologist

    aims to improve clinical outcomes for pediatric kidney transplant recipients through research in personalized care and the design of systems capable of delivering that care with high reliability. His primary focus is the prevention of cardiovascular disease through a combination of quality improvement and clinical/translational research methods.

    513-636-4531
    david.hooper@cchmc.org

    David K. Hooper, MD, MS

    Pediatric Nephrologist

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4531

    Fax: 513-636-7407

    Email: david.hooper@cchmc.org

    Show All

    Specialties

    Nephrology; kidney transplantation; quality improvement

    Biography

    Jointly appointed in the Division of Nephrology and Hypertension and the James M. Anderson Center for Health Systems Excellence at Cincinnati Children’s Hospital, Dr. Hooper's aim is to improve clinical outcomes for pediatric kidney transplant recipients through research in personalized care and the design of reliable healthcare systems.

    Dr. Hooper's research training includes a Masters Degree in clinical and translational research from the University of Cincinnati, in addition to advanced training in quality improvement methodology through the Quality Scholars in Healthcare Transformation program at Cincinnati Children’s Hospital.

    Dr. Hooper's career focus is to combine clinical outcomes research with quality improvement to reliably prevent cardiovascular disease, the leading cause of long-term death and disability in pediatric transplant recipients.

    Education and Training

    MD: University of Utah, Salt Lake City, Utah, 2003.

    Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2006.

    Chief Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2007.

    MS: University of Cincinnati, Cincinnati, Ohio, 2010.

    Fellowship: Cincinnati Children's Hospital, Cincinnati Ohio, 2010; Quality Scholar in Healthcare Transformation, James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital, Cincinnati, Ohio, 2011.

    Certification: Pediatrics, 2006.

    Publications

    View PubMed Publications

    Grants

    A Reliable System for Blood Pressure Control. Principal Investigator. KL2 Research Scholars (8KL2TR000078-04), Center for Clinical and Translational Science Training, University of Cincinnati. Apr 2012 - Mar 2014.

    A Reliable System for Blood Pressure Control. Principal Investigator. Place Outcomes Research Award. James M. Anderson Center for Health Systems Excellence. Cincinnati Children’s Hospital Medical Center. Jul 2012 - Jun 2014.

    A photo of Elizabeth Jackson.

    Elizabeth C. Jackson, MD Director, Healthy Bladder Clinic

    has clinical research in types of bedwetting alarms that are useful for nocturnal enuresis, in outcomes of neurogenic bladder, and in the relationship of obesity and kidney stones as well as industry sponsored research in anticholinergics for neurogenic bladder.

    513-636-4975
    elizabeth.jackson@cchmc.org

    Elizabeth C. Jackson, MD

    Director, Healthy Bladder Clinic

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-4975

    Fax: 513-636-6753

    Email: elizabeth.jackson@cchmc.org

    Show All

    Specialties

    Functional bladder disorders; neurogenic bladder; urolithiasis 

    Biography

    Elizabeth C. Jackson, MD, is a pediatric nephrologist recognized in the need for bladder management. Dr. Jackson has recently discontinued her inpatient nephrology role, and is currently focused on outpatient lower urinary tract management. She is the director of the Healthy Bladder Clinic at Cincinnati Children's. The Healthy Bladder Clinic cares for children with functional lower urinary tract disorders. There are more than 1200 visits per year to this clinic.

    Education and Training

    MD: University of Virginia, Charlottesville, Virginia, 1978.

    Residency: Children's Hospital of Pittsburgh, Pittsburgh, PA, 1981.

    Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 1984.

    Certification: Pediatrics, 1983; Pediatric Nephrology, 1985.

    Publications

    View PubMed Publications

    Grants

    Comparison of voice and buzzer alarms for nocturnal enuresis. Principal Investigator. Cincinnati Children's Hospital Medical Center. Oct 2011 - present.
    A photo of Paul T. McEnery, MD.

    Paul T. McEnery, MD, MBA

    has focused his career on the research of membranoproliferative glomerulonephritis and is a key member of the North American Pediatric Renal Transplant Consortium data base. Besides his research in transplantation and immune-mediated renal disease, he also was responsible for bringing the Ronald McDonald House to Cincinnati Children's as well as initiating dialytic therapy for children in Cincinnati.

    513-636-8652
    paul.mcenery@cchmc.org

    Paul T. McEnery, MD, MBA

    Academic Information

    UC Department of Pediatrics

    Emeritus Professor of Pediatrics

    Phone: 513-636-8652

    Fax: 513-636-7407

    Email: paul.mcenery@cchmc.org

    Show All

    Specialties

    Glomerulonephritis; vitamin D resistant rickets; care of the child with end-stage renal disease

    Education and Training

    MD: Loyola University, Chicago, IL, 1965. 

    Residency: Children's Hospital Medical Center, Cincinnati, OH.

    Fellowship: Nephrology, Children's Hospital Medical Center, Cincinnati, OH.

    Certification: Pediatrics 1974, 1986, 1993; Pediatric Nephrology, 1974, 1986, 1993.

    MBA: Xavier University, 1989.

    Publications

    View PubMed Publications
    A photo of Mark Mitsnefes.

    Mark M. Mitsnefes, MD, MS Director, Clinical and Translational Research Center

    is an established clinical investigator with expertise in the area of understanding the development of risk factors for cardiovascular disease in children with chronic kidney disease. The long-term goal of his research is to define biologic targets for interventions to prevent and slow progression of cardiovascular disease in children with chronic kidney disease.

    513-636-0125
    mark.mitsnefes@cchmc.org

    Mark M. Mitsnefes, MD, MS

    Director, Clinical and Translational Research Center

    Pediatric Nephrologist

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-0125

    Fax: 513-636-7407

    Email: mark.mitsnefes@cchmc.org

    Show All

    Specialties

    Nephrology with focus on chronic kidney disease and hypertension

    Biography

    Mark Mitsnefes, MD, MS, is an established clinical investigator with expertise in the area of understanding the development of risk factors for cardiovascular disease in children with chronic kidney disease. The long-term goal of his research is to define biologic targets for interventions to prevent and slow progression of cardiovascular disease in children with chronic kidney disease.

    Dr. Misnefes has received numerous awards, including the Proctor Scolar Award (Cincinnati Children's Research Foundation), the Pediatrician Scientist Award (Children's Health Research Center, NIH), the Clinical Scientist Award (National Kidney Foundation), and has been ranked as one of the Best Doctors in America, 2007-2011.

    Education and Training

    MD: Gorky Medical Institute, Gorky, Russia, 1985.

    Residency: Miami Children's Hospital, Miami, Florida, 1997.

    Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2000.

    MS: Epidemiology and Biostatistics, University of Cincinnati, Cincinnati, Ohio, 2001.

    Certifications: Educational Commission for Foreign Medical Graduates (ECFMG), 1995; Pediatrics, 1996; Pediatric Nephrology, 2001, 2008.

    Publications

    View PubMed Publications

    Grants

    Adiponectin and Cardiovascular Disease in the CKiD Children. Principal Investigator. National Institutes of Health. 2007 - 2011. #R01 DK076957.

    Modify Dietary Behavior in Adolescents with Elevated Blood Pressure. Co-investigator. National Institutes of Health. 2007 - 2012.

    Prospective study of chronic kidney disease in children. Co-investigator, Co-chair of the Cardiovascular Committee. National Institutes of Health. 2003 - 2013. #U01 DK-03-012.

    Cardiovascular disease in children with CKD. Principal Investigator. National Institutes of Health. 2011 - 2016. #K24 DK090070-01.

    DefaultUserSmall

    Edward J. Nehus, MD, MS Pediatric Nephrologist

    is a pediatric nephrologist who has conducted clinical research in chronic kidney disease and critical care nephrology.  His primary area of research is studying pharmacokinetic alterations in critically ill children receiving continuous renal replacement therapy.  Other research interests include studying cardiovascular risk factors and glomerular filtration rate estimation in children with chronic kidney disease.

    513-636-4531
    edward.nehus@cchmc.org

    Edward J. Nehus, MD, MS

    Pediatric Nephrologist

    Academic Information

    Instructor, UC Department of Pediatrics

    Phone: 513-636-4531

    Email: edward.nehus@cchmc.org

    Show All

    Specialties

    Critical care nephrology; chronic kidney disease

    Biography

    Edward conducted and published a cross-sectional study which investigated the association of serum resistin with cardiovascular risk factors in children with chronic kidney disease.  In addition, he recently published a study evaluating the outcomes steroid-avoidance protocols in pediatric kidney transplant recipients.  He continues to be the primary investigator for ongoing studies that explore pharmacokinetic alterations in critically ill children receiving continuous renal replacement therapy.

    Education and Training

    MD: University of Toledo, Toledo, OH, 2002.

    MS: University of Cincinnati, Cincinnati, OH, 2011.

    Residency: Pediatrics, Nationwide Children’s Hospital, Columbus, OH.

    Certification: Pediatrics, 2009.

    Fellowship: Pediatric Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

    Publications

    View PubMed Publications
    A photo of Frederic Strife.

    C. Frederic Strife, MD Emeritus Professor

    has focused his research career around immune-mediated renal disease and membranoproliferative glomerulonephritis in particular. Furthermore, Dr. Strife also has been active in understanding how to improve the care of the pediatric dialysis patient.

    513-636-4531
    fred.strife@cchmc.org

    C. Frederic Strife, MD

    Emeritus Professor

    Director of the Dialysis Unit

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-4531

    Fax: 513-636-7407

    Email: fred.strife@cchmc.org

    Show All

    Specialties

    Glomerulonephritis; renal tubular disorders; growth failure in chronic renal disease; dialysis

    Education and Training

    MD: College of Medicine and Dentistry of New Jersey, 1968.

    Residency: Pediatrics, Children's Hospital Medical Center, Cincinnati, OH.

    Fellowship: Nephrology, Children's Hospital Medical Center, Cincinnati, OH.

    Certification: Pediatrics, 1973; Pediatric Nephrology, 1976.

    Publications

    View PubMed Publications
    A photo of Rene Van de Voorde.

    Rene G. Van De Voorde III, MD Medical Director, Dialysis Unit

    focuses on clinical research in the sequelae, treatment, and outcomes of chronic kidney disease, including end stage renal disease. He is currently involved in drug trials and research projects on the treatment of anemia (2 studies), bone and mineral disease (3 studies), poor growth, cardiovascular disease, and quality of life (1 study each).

    513-636-4531
    rene.vandevoorde@cchmc.org

    Rene G. Van De Voorde III, MD

    Medical Director, Dialysis Unit

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4531

    Fax: 513-636-7407

    Email: rene.vandevoorde@cchmc.org

    Show All

    Specialties

    Dialysis; primarily infant dialysis; chronic kidney disease; acute kidney injury; hypertension

    Education and Training

    MD: Vanderbilt University.

    Residency: Pediatrics, Cincinnati Children's Hospital.

    Chief Resident: Pediatrics, Cincinnati Children's Hospital.

    Fellowship: Pediatric Nephrology, Cincinnati Children's Hospital.

    Certification: Pediatrics, 2003; Pediatric Nephrology, 2008.

    Publications

    View PubMed Publications

    Grants

    Prospective, Multicenter Study to Evaluate the Safety of Vitamin D Receptor Activators as Determined by Hypercalcemia in Pediatric Patients ages 0 to 16 with Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis within Current Clinical Practice. Site- Principal Investigator. Jun 2010 - present.

    Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Dialysis dependent Chronic Kidney Disease. Site Co-investigator. AMAG Pharmaceutical. Apr 2011 - present.

    Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Non-dialysis dependent Chronic Kidney Disease. Site-Principal Investigator. AMAG Pharmaceuticals. Apr 2011 - present.